Amikacin

Amikin is used for the short-term treatment of serious infections caused by susceptible strains of Gram-negative bacteria. It is effective in bacterial septicemia (including neonatal sepsis) and in serious infections of the respiratory tract, bones and joints, and central nervous system (including meningitis), as well as skin and soft tissue infections. It is also used for intra-abdominal infections (including peritonitis), and for infections associated with burns and postoperative or postvascular surgery. Clinical studies have shown Amikin to be effective as well in serious, complicated, and recurrent urinary tract infections caused by these organisms. Amikin has proven effective against infections caused by strains of Gram-negative organisms resistant to gentamicin and/or tobramycin, particularly Proteus rettgeri, Providencia stuartii, Serratia marcescens, and Pseudomonas aeruginosa. Amikin has also been shown to be effective against staphylococcal infections and may be considered for initial therapy in certain situations involving known or suspected staphylococcal disease, such as severe infections in which the causative organism may be either a Gram-negative bacterium or a staphylococcus.